UK AZN Overview Stock Screener Earnings Calendar Sectors Search Ticker | AZNU.K.: London Watchlist You must be logged in to create alerts Closed Last Updated:Jan 7, 2025 4:39 p.m.GMTDelayed quote p10,668 -44-0.41% Previous Close
Hardman & Co Insight: Survival of the UK life sciences sector For two years running, the Hardman & Co Healthcare index has declined, underperforming both the FTSE... View report 9 November 2023 In-line Q3; strong operational performance prompts outlook upgrade The Q3 results were in line with...
Data as of Jan 10 2025. Currency figures normalised to AstraZeneca PLC's reporting currency: UK Pound GBX 21.62%Per cent of shares held by top holders HolderShares% Held BlackRock Investment Management (UK) Ltd.as of 31 Dec 202368.51m4.42% ...
AstraZeneca PLC Price AstraZeneca PLC price|AstraZeneca PLC Quote Zacks Rank & Key Picks AstraZeneca carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector includeArcturus TherapeuticsARCT,BioventusBVSandFulcrum TherapeuticsFULC, each sporting a Zacks Rank #1 (...
ASTRAZENECA, the UK's number two drug company, has one of the richest share price valuations in the pharmaceuticals industry - and its results this week will go some way to showing whether this is justified.Foley, Stephen
AstraZeneca warns of shifting UK vaccine production to US Deadlock with the new Labour government over plans to cut state aid, the Financial Times reported on Thursday Fri Aug 23 2024 - 07:21 Ryanair dominates Irish market with share buyback announcement ...
The Discovery Centre in Cambridge (UK) is one of our global science centres Explore all our science centres Sustainability at AstraZeneca Corporate Press Release Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following...
The National Institute for Health and Care Excellence (NICE) decided in March this year that patients should be denied access to Enhertu because it said the drug did not provide value for money.
AstraZeneca AstraZeneca PLC Public LSE, NYSE and OMX: AZNFounded6 April 1999 by mergerHeadquartersLondon, England, UKKey peopleDavid Brennan CEOTony Zook
Following the vaccine’s UK approval, AlphaValue analyst Amandeep Goyal upgraded the stock to Buy from Sell as he argues that “sentiment around Astra’s share price should improve finally.” Goyal also raised AZN’s premium on peer-based multiples to 40% from 35% to account f...